Perjeta
E46091
Perjeta is a monoclonal antibody drug used in combination therapies to treat HER2-positive breast cancer.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Perjeta canonical | 6 |
How this entity was disambiguated
This entity first appeared as the object of triple T363288 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Perjeta Context triple: [Genentech, notableProduct, Perjeta]
-
A.
Leto
Leto is a Titaness in Greek mythology best known as the mother of the twin Olympian deities Apollo and Artemis.
-
B.
Day
"Day" is a memoir by Elie Wiesel that continues his reflection on Holocaust survival and its psychological aftermath, following the events depicted in "Night."
-
C.
Madruga
Madruga is a municipality in western Cuba known for its rural character and location within the historical region surrounding Havana.
-
D.
Juché
Juché is an alternative spelling of Juche, the North Korean state ideology centered on self-reliance and the absolute leadership of the Kim dynasty.
-
E.
Brega
Brega is a strategic coastal town in northeastern Libya known for its major oil facilities and its role as a key battleground during the 2011 Libyan Civil War.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Perjeta Target entity description: Perjeta is a monoclonal antibody drug used in combination therapies to treat HER2-positive breast cancer.
-
A.
Leto
Leto is a Titaness in Greek mythology best known as the mother of the twin Olympian deities Apollo and Artemis.
-
B.
Day
"Day" is a memoir by Elie Wiesel that continues his reflection on Holocaust survival and its psychological aftermath, following the events depicted in "Night."
-
C.
Madruga
Madruga is a municipality in western Cuba known for its rural character and location within the historical region surrounding Havana.
-
D.
Juché
Juché is an alternative spelling of Juche, the North Korean state ideology centered on self-reliance and the absolute leadership of the Kim dynasty.
-
E.
Brega
Brega is a strategic coastal town in northeastern Libya known for its major oil facilities and its role as a key battleground during the 2011 Libyan Civil War.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
HER2-targeted therapy
ⓘ
antineoplastic agent ⓘ monoclonal antibody drug ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| belongsToRegimen | CLEOPATRA regimen ⓘ |
| bindsTo | HER2 dimerization domain ⓘ |
| blackBoxWarning | embryo-fetal toxicity ⓘ |
| clinicalTrial |
APHINITY trial
ⓘ
CLEOPATRA trial ⓘ |
| commonAdverseEffect |
alopecia
ⓘ
diarrhea ⓘ fatigue ⓘ nausea ⓘ neutropenia ⓘ rash ⓘ |
| contraindication | pregnancy ⓘ |
| EMAPositiveOpinionYear | 2013 ⓘ |
| FDAApprovalYear | 2012 ⓘ |
| hasAntibodyType | IgG1 ⓘ |
| hasATCCode | L01FD02 ⓘ |
| hasDosageForm | concentrate for solution for infusion ⓘ |
| hasDrugClass | humanized monoclonal antibody ⓘ |
| hasGenericName | pertuzumab ⓘ |
| hasManufacturer | Genentech ⓘ |
| hasMolecularType | recombinant humanized monoclonal antibody ⓘ |
| hasParentCompany | Roche ⓘ |
| hasTarget |
ERBB2
ⓘ
HER2 receptor ⓘ |
| improvesOutcome |
overall survival in HER2-positive metastatic breast cancer
ⓘ
progression-free survival in HER2-positive metastatic breast cancer ⓘ |
| indication |
HER2-positive early breast cancer
ⓘ
HER2-positive locally advanced breast cancer ⓘ HER2-positive metastatic breast cancer ⓘ |
| inhibits | HER2 dimerization ⓘ |
| isPatentProtected | true ⓘ |
| mechanismOfAction |
induces antibody-dependent cell-mediated cytotoxicity
ⓘ
inhibits HER2 signaling pathways ⓘ prevents ligand-dependent HER2 heterodimerization ⓘ |
| regulatoryStatus | prescription-only medicine ⓘ |
| requiresMonitoring | left ventricular ejection fraction ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| seriousAdverseEffect |
congestive heart failure
ⓘ
left ventricular dysfunction ⓘ |
| usedInCombinationWith |
chemotherapy
ⓘ
docetaxel ⓘ trastuzumab ⓘ
linked to:
Herceptin
|
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Perjeta Description of subject: Perjeta is a monoclonal antibody drug used in combination therapies to treat HER2-positive breast cancer.
Referenced by (6)
Full triples — surface form annotated when it differs from this entity's canonical label.